Only 1 patient required re-treatment after 6 months.
QT Vascular revealed that its newest drug coated coronary balloon, Chocolate Heart, posted encouraging results at recent clinical trials.
Procedural outcomes demonstrated zero incidence of bail-out stent placement, significant dissection, abrupt closure, and sub-acute occlusion.
At 30 days, the overall rate of major adverse coronary events was 0%. At 6 months, only 1 patient needed re-treatment and the average late lumen loss was 0.02mm.
“While this is an early feasibility study and larger confirmatory studies will be needed, these preliminary results are very encouraging as they hint at the possibility of being able to offer an effective treatment to patients with de novo coronary disease without the use of a permanent implant, such as a metallic stent or a bioresorbable scaffold, which may take years to dissolve,” stated Professor Bruno Scheller of the University of Saarland in Homburg/Saar, Germany.
Do you know more about this story? Contact us anonymously through this link.